AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. The FDA has now started a ...

First-in-class iberdomide has been given accelerated approval under the Zenbexus brand name, alongside Johnson & Johnson and ...

Skylark Bio has started dosing patients in a phase 1/2 trial of SKY-GJB2, a one-shot gene therapy designed to treat ...

The FDA has published its long-awaited update to guidance to make sure clinical trials more closely reflect the range of patients that might be treated with a new therapy in the real world. The draft ...

Shares in ADC Therapeutics were trading down more than 50% today after a non-Hodgkin lymphoma (NHL) trial showed more deaths with its Zynlonta drug compared to standard therapy. The LOTIS-5 trial is ...

A year ago, Astellas was celebrating the first-in-class approval of its claudin 18.2-targeting cancer drug Vyloy for gastric cancers. Now, a bid to expand its label into pancreatic cancer has hit the ...

Indeed, GLP-1 therapies currently bring with them the inconvenience of subcutaneous injections, the difficulty of titration, ...

There’s a personalisation crisis in today’s marketing. Nearly 99% of marketers believe personalisation helps strengthen ...

AbbVie, Bristol Myers Squibb, and Novartis have filed separate lawsuits in Illinois, each seeking to overturn a recently ...

Actio is the third acquisition for Jazz in the last few years, coming after it bought Chimerix for $935 million last year and ...

After reporting mixed clinical results in a phase 3 trial, Pfizer and Valneva have filed their Lyme disease vaccine candidate PF-07307405 in the EU, and the EMA has started its review. The six-valent ...

Autolomous is a UK-based company pioneering cloud-native and AI-enhanced digitisation of life sciences manufacturing and ...